Hutchison China MediTech Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hutchison China MediTech Limited
Legend/J&J’s CAR-T cilta-cel and Chi-Med’s surufatinib would follow BeiGene’s Brukinsa, which won FDA approval in November 2019.
EcoR1 and Casdin/Corvex took their second and third special purpose acquisition corporations public. Also, Ionis sold notes to buy back older notes and fund operations as it cut 70% of Akcea’s staff. In venture capital, ValenzaBio raised $70m and RA boosted Metagenomi’s series A to $75m.
A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.
Throughout 2020, China’s drive to introduce more and newer drugs to the market did not slow but was rather accelerated by the COVID-19 pandemic. But can people afford them?
- OTC, Consumer
- Other Names / Subsidiaries
- Hutchison Whampoa Sinopharm Pharmaceuticals Company Limited
- Hutchison MediPharma Limited